{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:19:21Z","timestamp":1777493961682,"version":"3.51.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","award":["118\/2013\/A3"],"award-info":[{"award-number":["118\/2013\/A3"]}],"id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.ejps.2017.03.037","type":"journal-article","created":{"date-parts":[[2017,3,27]],"date-time":"2017-03-27T18:02:22Z","timestamp":1490637742000},"page":"101-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["SLM, a novel carbazole-based fluorophore attenuates okadaic acid-induced tau hyperphosphorylation via down-regulating GSK-3\u03b2 activity in SH-SY5Y cells"],"prefix":"10.1016","volume":"110","author":[{"given":"Xiaoli","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayasankar","family":"Kosaraju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kin Yip","family":"Tam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2017.03.037_bb0005","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.febslet.2011.03.025","article-title":"Selective loss of glycogen synthase kinase-3\u03b1 in birds reveals distinct roles for GSK-3 isozymes in tau phosphorylation","volume":"585","author":"Alon","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejps.2017.03.037_bb0010","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jalz.2012.02.001","article-title":"2012 Alzheimer's disease facts and figures","volume":"8","author":"Association, A.s","year":"2012","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.ejps.2017.03.037_bb0015","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jalz.2016.03.001","article-title":"2016 Alzheimer's disease facts and figures","volume":"12","author":"Association, A.s","year":"2016","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.ejps.2017.03.037_bb0020","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/srep00480","article-title":"Hypothermia-induced hyperphosphorylation: a new model to study tau kinase inhibitors","volume":"2","author":"Bretteville","year":"2012","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejps.2017.03.037_bb0025","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.neuropharm.2010.01.016","article-title":"Tau protein and tau aggregation inhibitors","volume":"59","author":"Bulic","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejps.2017.03.037_bb0030","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.nbd.2011.09.002","article-title":"Activation of glycogen synthase kinase-3 beta mediates beta-amyloid induced neuritic damage in Alzheimer's disease","volume":"45","author":"DaRocha-Souto","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejps.2017.03.037_bb0035","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1111\/j.1460-9568.2012.08084.x","article-title":"Microtubule stabilization by peloruside A and paclitaxel rescues degenerating neurons from okadaic acid-induced tau phosphorylation","volume":"35","author":"Das","year":"2012","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.ejps.2017.03.037_bb0040","doi-asserted-by":"crossref","first-page":"28912","DOI":"10.1038\/srep28912","article-title":"Alzheimer's disease AdvaxCpG-adjuvanted MultiTEP-based dual and single vaccines induce high-titer antibodies against various forms of tau and A\u03b2 pathological molecules","volume":"6","author":"Davtyan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejps.2017.03.037_bb0045","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2017.03.037_bb0050","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1096\/fj.08-120410","article-title":"\u03b1-Synuclein contributes to GSK-3\u03b2-catalyzed Tau phosphorylation in Parkinson's disease models","volume":"23","author":"Duka","year":"2009","journal-title":"FASEB J."},{"key":"10.1016\/j.ejps.2017.03.037_bb0055","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jpsychires.2010.06.002","article-title":"Increased platelet GSK3B activity in patients with mild cognitive impairment and Alzheimer's disease","volume":"45","author":"Forlenza","year":"2011","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.ejps.2017.03.037_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094259","article-title":"Extracellular \u03b1-synuclein leads to microtubule destabilization via GSK-3\u03b2-dependent tau phosphorylation in PC12 cells","volume":"9","author":"G\u0105ssowska","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejps.2017.03.037_bb0065","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.tox.2016.03.002","article-title":"Perinatal exposure to lead (Pb) promotes tau phosphorylation in the rat brain in a GSK-3\u03b2 and CDK5 dependent manner: relevance to neurological disorders","volume":"347","author":"G\u0105ssowska","year":"2016","journal-title":"Toxicology"},{"key":"10.1016\/j.ejps.2017.03.037_bb0070","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.2174\/092986708785909111","article-title":"Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer disease","volume":"15","author":"Gong","year":"2008","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejps.2017.03.037_bb0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.nbd.2016.10.004","article-title":"Tau hyperphosphorylation in the brain of ob\/ob mice is due to hypothermia: importance of thermoregulation in linking diabetes and Alzheimer's disease","volume":"98","author":"Gratuze","year":"2017","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejps.2017.03.037_bb0080","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/00005072-199609000-00003","article-title":"Reduction of acetylated alpha-tubulin immunoreactivity in neurofibrillary tangle-bearing neurons in Alzheimer's disease","volume":"55","author":"Hempen","year":"1996","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ejps.2017.03.037_bb0085","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3233\/JAD-130545","article-title":"Microtubule depolymerization and tau phosphorylation dedicated to Inge Grundke-Iqbal","volume":"37","author":"Hernandez","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.ejps.2017.03.037_bb0090","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.pharmthera.2012.07.001","article-title":"Tau as a therapeutic target in neurodegenerative disease","volume":"136","author":"Himmelstein","year":"2012","journal-title":"Pharmacol. Therapeut."},{"key":"10.1016\/j.ejps.2017.03.037_bb0095","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbrc.2012.08.042","article-title":"Glycogen synthase kinase-3\u03b2 activation mediates rotenone-induced cytotoxicity with the involvement of microtubule destabilization","volume":"426","author":"Hongo","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejps.2017.03.037_bb0100","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.nbd.2008.10.007","article-title":"GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals","volume":"33","author":"Hu","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejps.2017.03.037_bb0105","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.brainresbull.2011.03.006","article-title":"Valproate reduces tau phosphorylation via cyclin-dependent kinase 5 and glycogen synthase kinase 3 signaling pathways","volume":"85","author":"Hu","year":"2011","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.ejps.2017.03.037_bb0110","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/j.1460-2075.1993.tb05715.x","article-title":"Modulation of the glycogen-synthase kinase-3 family by tyrosine phosphorylation","volume":"12","author":"Hughes","year":"1993","journal-title":"EMBO J."},{"key":"10.1016\/j.ejps.2017.03.037_bb0115","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.neuropharm.2014.05.032","article-title":"Temsirolimus attenuates tauopathy in vitro and in vivo by targeting tau hyperphosphorylation and autophagic clearance","volume":"85","author":"Jiang","year":"2014","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ejps.2017.03.037_bb0120","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1007\/s12035-014-8699-4","article-title":"Molecular and cellular mechanism of okadaic acid (OKA)-induced neurotoxicity: a novel tool for Alzheimer's disease therapeutic application","volume":"50","author":"Kamat","year":"2014","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejps.2017.03.037_bb0125","doi-asserted-by":"crossref","first-page":"4787","DOI":"10.1007\/s12035-015-9405-x","article-title":"Combination of PKC epsilon activation and PTP1B inhibition effectively suppresses A beta-induced GSK-3 beta activation and tau phosphorylation","volume":"53","author":"Kanno","year":"2016","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejps.2017.03.037_bb0130","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1124\/jpet.115.231175","article-title":"Characterization of brain-penetrant pyrimidine-containing molecules with differential microtubule-stabilizing activities developed as potential therapeutic agents for Alzheimer's disease and related tauopathies","volume":"357","author":"Kovalevich","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2017.03.037_bb0135","doi-asserted-by":"crossref","first-page":"9673","DOI":"10.1073\/pnas.0602913103","article-title":"An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice","volume":"103","author":"Le Corre","year":"2006","journal-title":"P. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejps.2017.03.037_bb0140","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.nbd.2013.01.002","article-title":"Ginsenoside Rd attenuates beta-amyloid-induced tau phosphorylation by altering the functional balance of glycogen synthase kinase 3beta and protein phosphatase 2A","volume":"54","author":"Li","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejps.2017.03.037_bb0145","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.neuroscience.2015.03.005","article-title":"Lovastatin suppresses the aberrant tau phosphorylation from FTDP-17 mutation and okadaic acid-induction in rat primary neurons","volume":"294","author":"Li","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejps.2017.03.037_bb0150","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.bbrc.2010.03.163","article-title":"Maintained activity of glycogen synthase kinase-3\u03b2 despite of its phosphorylation at serine-9 in okadaic acid-induced neurodegenerative model","volume":"395","author":"Lim","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejps.2017.03.037_bb0155","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1007\/s00415-017-8395-1","article-title":"Treatments in Alzheimer's disease","volume":"264","author":"Malik","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.ejps.2017.03.037_bb0160","doi-asserted-by":"crossref","first-page":"6990","DOI":"10.1073\/pnas.0500466102","article-title":"Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo","volume":"102","author":"Noble","year":"2005","journal-title":"P. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ejps.2017.03.037_bb0165","doi-asserted-by":"crossref","DOI":"10.1093\/hmg\/ddv212","article-title":"I2020T mutant LRRK2 iPSC-derived neurons in the Sagamihara family exhibit increased tau phosphorylation through the AKT\/GSK-3\u03b2 signaling pathway","author":"Ohta","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejps.2017.03.037_bb0170","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s12035-015-9640-1","article-title":"Phosphatase 2A inhibition affects endoplasmic reticulum and mitochondria homeostasis via cytoskeletal alterations in brain endothelial cells","volume":"54","author":"Pl\u00e1cido","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.ejps.2017.03.037_bb0175","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/anie.201410456","article-title":"Multitarget drug discovery for Alzheimer's disease: triazinones as BACE-1 and GSK-3 beta inhibitors","volume":"54","author":"Prati","year":"2015","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejps.2017.03.037_bb0180","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1016\/S0140-6736(16)32107-9","article-title":"Targeting tau protein in Alzheimer's disease","volume":"388","author":"Rafii","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejps.2017.03.037_bb0185","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3390\/vaccines2030601","article-title":"Doubly phosphorylated peptide vaccines to protect transgenic P301S mice against Alzheimer's disease like tau aggregation","volume":"2","author":"Richter","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.ejps.2017.03.037_bb0190","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2017.03.037_bb0195","doi-asserted-by":"crossref","DOI":"10.1111\/joim.12191","article-title":"Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014","volume":"275","author":"Schneider","year":"2014","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ejps.2017.03.037_bb0200","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3233\/JAD-2012-120805","article-title":"Treatment of Alzheimer's disease with the GSK-3 inhibitor Tideglusib: a pilot study","volume":"33","author":"del Ser","year":"2013","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.ejps.2017.03.037_bb0205","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.nbd.2009.05.025","article-title":"A novel GSK-3\u03b2 inhibitor reduces Alzheimer's pathology and rescues neuronal loss in vivo","volume":"35","author":"Seren\u00f3","year":"2009","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejps.2017.03.037_bb0210","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.nbd.2011.12.050","article-title":"Long-term oral lithium treatment attenuates motor disturbance in tauopathy model mice: implications of autophagy promotion","volume":"46","author":"Shimada","year":"2012","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.ejps.2017.03.037_bb0215","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1042\/bj3030701","article-title":"Mitogen inactivation of glycogen-synthase kinase-3-beta in intact-cells via serine-9 phosphorylation","volume":"303","author":"Stambolic","year":"1994","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejps.2017.03.037_bb0220","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1021\/ja00399a082","article-title":"Okadaic acid, a cytotoxic polyether from two marine sponges of the genus Halichondria","volume":"103","author":"Tachibana","year":"1981","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejps.2017.03.037_bb0225","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1021\/acschemneuro.6b00388","article-title":"Neuroprotective effect of SLM, a novel carbazole-based fluorophore, on SH-SY5Y cell model and 3xTg-AD mouse model of Alzheimer's disease","volume":"8","author":"Wu","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejps.2017.03.037_bb0230","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1002\/anie.201104150","article-title":"Inhibition of beta-amyloid peptide aggregation by multifunctional carbazole-based fluorophores","volume":"51","author":"Yang","year":"2012","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejps.2017.03.037_bb0235","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1007\/s11064-014-1410-3","article-title":"Protective effects of humanin on okadaic acid-induced neurotoxicities in cultured cortical neurons","volume":"39","author":"Zhao","year":"2014","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ejps.2017.03.037_bb0240","doi-asserted-by":"crossref","first-page":"497","DOI":"10.4155\/bio-2015-0014","article-title":"Quantification of permanent positively charged compounds in plasma using one-step dilution to reduce matrix effect in MS","volume":"8","author":"Zhou","year":"2016","journal-title":"Bioanalysis"}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717301720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717301720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T20:43:18Z","timestamp":1536698598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098717301720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":48,"alternative-id":["S0928098717301720"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2017.03.037","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SLM, a novel carbazole-based fluorophore attenuates okadaic acid-induced tau hyperphosphorylation via down-regulating GSK-3\u03b2 activity in SH-SY5Y cells","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2017.03.037","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}